Development and clinical overview of trastuzumab (herceptin).
To provide a review of the two pivotal clinical trials evaluating trastuzumab in metastatic breast cancer, either in combination with chemotherapy or as a single agent. Research reports. Trastuzumab is indicated as a single agent or in combination with chemotherapy for patients with metastatic breast cancer who overexpress the HER2 protein. The toxicity profile of trastuzumab is favorable; cardiac dysfunction has been the primary dose-limiting toxicity, especially when combined with anthracyclines. Nurses will deliver trastuzumab in the clinical setting and must be familiar with its efficacy and toxicity profile.